drugset / Trial / NCT01496690
Pregablin for Anxiety-comorbidity in Patients With Schizophrenia
Phase 4
Completed
54 enrolled
University of Aarhus
Albert Einstein College of Medicine · collabGCP-unit at Aarhus University Hospital, Aarhus, Denmark · collabPfizer · collabThe Hospital Pharmcacy North Denmark Region, Denmark · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The PACS study aims to investigate the efficacy and tolerability of pregabalin for schizophrenic patients that suffer from comorbid anxiety. The study design is an 8 week flexible dosage, randomized placebo controlled. The study population is patients diagnosed with ICD-10 schizophrenia and age 18-65. Patients are recruited from outpatient clinics from entire Denmark.
Timeline
- Start
- 2012-01
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pregabalin | Small molecule | 150 mg | — |
| Comparator | Pregabalin | Small molecule | 300 mg | — |
| Comparator | Pregabalin | Small molecule | 450 mg | — |
| Comparator | Pregabalin | Small molecule | 600 mg | — |